Ginkgo Bioworks Net Income Over Time
| DNA Stock | USD 8.91 0.38 4.09% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Ginkgo Bioworks Performance and Ginkgo Bioworks Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ginkgo Bioworks. Projected growth potential of Ginkgo fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Ginkgo Bioworks assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (6.18) | Revenue Per Share | Quarterly Revenue Growth (0.56) | Return On Assets | Return On Equity |
Understanding Ginkgo Bioworks Holdings requires distinguishing between market price and book value, where the latter reflects Ginkgo's accounting equity. The concept of intrinsic value - what Ginkgo Bioworks' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Ginkgo Bioworks' price substantially above or below its fundamental value.
It's important to distinguish between Ginkgo Bioworks' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Ginkgo Bioworks should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Ginkgo Bioworks' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Ginkgo Bioworks Holdings and related stocks such as Iovance Biotherapeutics, Replimune Group, and MBX Biosciences Common Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IOVA | (57.1 K) | (25.7 M) | (3.3 M) | (25.4 M) | (12 M) | (27.7 M) | (52.9 M) | (92.1 M) | (123.6 M) | (187.1 M) | (259.6 M) | (327.8 M) | (389.9 M) | (444 M) | (372.2 M) | (335 M) | (318.2 M) |
| REPL | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (19.7 M) | (30.8 M) | (52.6 M) | (80.9 M) | (118 M) | (174.3 M) | (215.8 M) | (247.3 M) | (222.6 M) | (211.4 M) |
| MBX | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (32.6 M) | (61.9 M) | (55.7 M) | (58.5 M) |
| MGTX | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (31 M) | (82.9 M) | (54.7 M) | (58 M) | (79.6 M) | (129.6 M) | (84 M) | (147.8 M) | (133 M) | (126.4 M) |
| AVBP | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (36.9 M) | (69.3 M) | (80.5 M) | (80.5 M) | (72.4 M) | (76.1 M) |
| MRVI | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (8.5 M) | 76.9 M | 182 M | 220.2 M | (119 M) | (144.8 M) | (130.4 M) | (123.8 M) |
| ATXS | (15.7 K) | (15.7 K) | (15.7 K) | (18.1 M) | (21.9 M) | (32.6 M) | (36.1 M) | (27.4 M) | (25.9 M) | (26.3 M) | (37.1 M) | (194.9 M) | (50.2 M) | (72.9 M) | (94.3 M) | (84.8 M) | (80.6 M) |
| VIR | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (115.9 M) | (174.7 M) | (298.7 M) | 528.6 M | 515.8 M | (615.1 M) | (522 M) | (469.8 M) | (446.3 M) |
| ARVN | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (24 M) | (41.5 M) | (62.1 M) | (111.8 M) | (183.2 M) | (271.9 M) | (367.3 M) | (198.9 M) | (179 M) | (188 M) |
| VALN | (1.2 M) | (4.4 M) | (14.8 M) | (24.1 M) | (26.3 M) | (20.6 M) | (49.2 M) | (11.5 M) | 3.3 M | (1.7 M) | (64.4 M) | (73.4 M) | (143.3 M) | (101.4 M) | (12.2 M) | (11 M) | (11.6 M) |
Ginkgo Bioworks Holdings and related stocks such as Iovance Biotherapeutics, Replimune Group, and MBX Biosciences Common Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Ginkgo Bioworks Holdings financial statement analysis. It represents the amount of money remaining after all of Ginkgo Bioworks Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Ginkgo Bioworks Holdings | DNA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 27 Drydock Avenue, |
| Exchange | New York Stock Exchange |
USD 8.91
Check out Ginkgo Bioworks Performance and Ginkgo Bioworks Correlation. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Ginkgo Bioworks technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.